QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings
PR96258
SHANGHAI, May 31, 2022 /PRNewswire=KYODO JBN/ --
QureBio Ltd., a clinical-stage biopharmaceutical company focusing on
bi-specific antibodies and other engineered bio-therapeutics for the treatment
of cancer, inflammation, and other serious disorders, today announced that its
Q-1802 clinical program was selected for presentation at American Society of
Clinical Oncology (ASCO) Annual Meetings on June 3–7, 2022, and the abstract of
relevant results for this study has been published on ASCO website
(https://meetings.asco.org/abstracts-presentations/210075).
The presentation will showcase the preliminary results of a first-in-human
Phase 1a/1b, multicenter, open-label oncology study designed to evaluate the
safety and anti-cancer activity Q-1802, a Claudin18.2/PD-L1 bi-specific
therapeutic in patients with relapsed or refractory solid tumors after standard
therapies. Professor Lin Shen from Peking University Cancer Hospital and
Institute leads this study. The key data from the mono-therapy of Q-1802 in
both dose-escalation and dose-expansion studies demonstrate excellent safety,
tolerability, and preliminary anti-tumor activities of Q-1802 at the dose up to
10 mpk.
The abstract for the study is found in 2022-ASCO-Annual –Meeting Abstracts
(#2568), and the poster session information is listed below. First Author, Dr.
Jifang Gong from the Department of Gastrointestinal Oncology, Peking University
Cancer Hospital and Institute will present the relevant results on Sunday, June
5, 2022.
Session Title: Developmental Therapeutics—Immunotherapy
Session Type: Poster Session
Date: Sunday, June 5, 2022
Time: 8:00 AM - 11:00 AM, Chicago Time (CDT)
Location: Hall A
Abstract ID (Temp. ID): 2568 (368426)
Poster Board #: 223
Role Responsibilities: Presenter
Primary Track: Developmental Therapeutics—Immunotherapy
Session begins on Jun 5, 2022 at 8:00 AM Chicago Time (CDT)
Room: Hall A-14355
Persons: Dr. Jifang Gong
Presenting from 8:00 AM - 11:00 AM, Chicago Time (CDT)
About Q-1802
Q-1802, a humanized bi-specific antibody, is the first FDA-approved
Claudin18.2/PD-L1 bi-specific therapeutic to enter clinical trial. In animal
model studies, Q-1802 demonstrates both superior anti-tumor activities and
excellent safety profiles. It recruits multiple immune mechanisms to kill tumor
cells, offering a novel therapeutic opportunity for Claudin18.2 positive solid
tumors. Q-1802 also exhibits robust physicochemical properties and superb
productivity with titers exceeding 4 grams per liter.
About QureBio Ltd.
QureBio Ltd. is a clinical-stage biopharmaceutical company focusing on
innovative biopharmaceuticals for urgent and unmet clinical needs, such as the
treatment of refractory cancers, inflammation and other serious disorders.
Founded by experienced scientists from the relevant fields, QureBio Ltd. has
built up a series of proprietary technologies for engineered
bio-macromolecules, including innovative platforms for bi-specific and
tri-specific antibodies.
Founded in 2017 with seed capital from Viva Bio-Innovator, QureBio Ltd. has
since received a series of funds from Jundu Investment, Watson Capital,
Shenzhen Capital Group, New value Capital, Bocom Industrial Investment
(Hangzhou) Equity Investment Partnership, Suzhou Oriza Holdings, Hangzhou
CAPITAL GuoShun, Zhuhai Longmen Capital Management, Shanghai Pudong Kechuang
Group, Shenzhen Lihe Hongxin Venture and Three Rivers Capital. QureBio Ltd. has
secured a Series-B funding of nearly 200 million CNY.
QureBio Ltd. engages in collaboration with partners to develop novel
therapeutics for unmet medical needs and has on-going cooperation with a series
of industrial partners including BRL Medicine, BioMap, Precision Scientific,
and Hengrui Pharmaceuticals, an industry leader in China.
Source: QureBio Ltd.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。